Momelotinib Approved in Canada for Myelofibrosis with Anemia

Health Canada has approved momelotinib查看药品详情 (Ojjaara查看药品详情) for the treatment of splenomegaly and disease-related symptoms in adult patients with intermediate- or high-risk primary myelofibrosis (搜索)搜索该疾病, post–polycythemia vera or essential thrombocythemia myelofibrosis who have moderate-to-severe anemia (搜索)搜索该疾病. This approval marks a significant advancement in treating myelofibrosis-related anemia, an area with limited therapeutic options.

The regulatory decision was primarily supported by data from the phase 3 MOMENTUM trial, a global, multicenter, randomized, double-blind study. The trial compared momelotinib查看药品详情 (n = 130) with danazol查看药品详情 (n = 65) in myelofibrosis (搜索)搜索该疾病 patients who were anemic, symptomatic, and had prior exposure to a JAK inhibitor. The results demonstrated a statistically significant improvement in total symptom score (TSS) reduction of at least 50% in 25% of patients in the momelotinib arm compared to 9% in the danazol arm (proportion difference, 16%; 95% CI, 6%-26%; P < .01).

Key Findings from MOMENTUM Trial

Momelotinib查看药品详情 also showed a higher rate of transfusion independence, with 30% of patients achieving independence between weeks 12 and 24, compared to 20% in the danazol查看药品详情 arm (noninferiority treatment difference, 14%; 95% CI, 2%-25%; P = .023). Furthermore, 35% of patients in the momelotinib arm required no transfusions during the 24-week treatment period, versus 17% in the danazol arm (treatment difference, 17%; 95% CI, 8%-26%; P = .001).

Significant spleen volume reduction (SVR) was also observed in the momelotinib查看药品详情 arm, with 39% of patients achieving at least a 25% reduction compared to 6% in the danazol查看药品详情 arm (treatment difference, 33%; 95% CI, 23%-44%; P < .0001). An SVR of at least 35% was seen in 22% of patients treated with momelotinib, versus 3% in the danazol group (treatment difference, 18%; 95% CI, 10%-27%; P = .001).

Additional Data from SIMPLIFY-1 Trial

Additional support for the approval came from a subset of patients with moderate to severe anemia (搜索)搜索该疾病 at baseline in the phase 3 SIMPLIFY-1 trial. This multicenter, randomized, double-blind study compared momelotinib查看药品详情 (n = 215) with ruxolitinib查看药品详情 (n = 217) in patients with myelofibrosis (搜索)搜索该疾病 who had not previously received a JAK inhibitor. The SIMPLIFY-1 trial indicated that 31.4% (95% CI, 21.8%-42.3%) of patients in the momelotinib arm achieved SVR35 compared to 32.6% (95% CI, 23.4%-43.0%) in the ruxolitinib arm. However, the percentage of patients treated with momelotinib who reported a TSS score reduction of at least 50% at week 24 was numerically lower than that of patients treated with ruxolitinib, at 25% vs 36%.

Expert Commentary

Michelle Horn, interim country medical director of GSK Canada (搜索)搜索该词条, stated, "Treatment options for myelofibrosis (搜索)搜索该疾病-related anemia (搜索)搜索该疾病 have been limited. We are proud to offer this treatment alternative for Canadian patients to address this critical unmet need and other myelofibrosis symptoms... With most [patients with] myelofibrosis becoming anemic over time, [momelotinib查看药品详情’s] approval represents a significant milestone to improve the outcomes of these patients while also highlighting GSK’s commitment to making an impact in Canada’s hematology oncology space through innovative new treatments."

Cheryl Petruk, chief executive officer of HEAL Canada, added, "Anemia (搜索)搜索该疾病 and related transfusions significantly affect the quality of life, prognosis, and survival for anemic [patients with] myelofibrosis (搜索)搜索该疾病... We are excited to witness progress in this rare disease space and to see [momelotinib查看药品详情] approved in Canada. This new treatment has the potential to help improve the lives of patients while addressing the disease’s main challenges, namely anemia and other major symptoms."